Tag: Cancer: Prostate
2008 to 2020 Saw Increase in Survival for Advanced Prostate Cancer
Shift in survival occurred during introduction of doublet therapy
Enzalutamide + Leuprolide Top for Mets-Free Survival in Prostate Cancer
Enzalutamide plus leuprolide superior for metastasis-free survival in prostate cancer with high-risk biochemical recurrence
ASTRO: Shorter Radiation Feasible for Low-, Intermediate-Risk Prostate Cancer
Findings at five years show 96 percent disease control rate
Survival Varies by Race, Ethnicity for Nonmetastatic Castration-Resistant Prostate Cancer
However, equal access to care through the Veterans Administration reduces, reverses disparities
When Health Care Access Is Equal, Race Gap in Prostate Cancer Survival Vanishes
Shorter Courses of Radiotherapy Increasingly Used for Prostate Cancer
Recent drop seen in proportion of patients receiving conventional fractionation; increase seen in moderate hypofractionation and ultrahypofractionation
Prostate-Specific Antigen Levels Posttreatment May Not Predict Overall Survival
Biochemical recurrence does not meet the criteria to be a reliable surrogate endpoint for overall survival
Common Cancer Screenings May Not Extend Life Longevity
Meta-analysis only shows a 110-day survival benefit for colorectal cancer screening with sigmoidoscopy
Prostate MRI Has Independent Screening Value
In a recent study, 16 percent of men who responded to screening invite had positive screening MRI
FDA Approves Akeega for BRCA-Positive Metastatic Prostate Cancer
Akeega plus prednisone significantly improves radiographic progression-free survival in patients with castration-resistant prostate cancer
